(All_Metastatic cohort)
This pipeline uses various statistical tests to identify genes whose promoter methylation levels correlated to selected clinical features.
Testing the association between 17129 genes and 7 clinical features across 168 samples, statistically thresholded by Q value < 0.05, 7 clinical features related to at least one genes.
-
1 gene correlated to 'Time to Death'.
-
NR4A3
-
7 genes correlated to 'AGE'.
-
ITGA8 , PTX3 , RSPO4 , SHANK1 , TRPV4 , ...
-
241 genes correlated to 'PRIMARY.SITE.OF.DISEASE'.
-
DAZAP1 , TCF3 , IRAK4 , PUS7L , TCF25 , ...
-
1 gene correlated to 'GENDER'.
-
DDX43
-
248 genes correlated to 'DISTANT.METASTASIS'.
-
SELT , LMF1 , FAM186A , LDHAL6B , CCNG1 , ...
-
50 genes correlated to 'LYMPH.NODE.METASTASIS'.
-
NGLY1 , C6ORF162 , LIMK2 , AP2S1 , C17ORF63 , ...
-
8 genes correlated to 'NEOPLASM.DISEASESTAGE'.
-
TTN , POLE4 , ZNF587 , RAD21L1 , C4ORF3 , ...
Complete statistical result table is provided in Supplement Table 1
Clinical feature | Statistical test | Significant genes | Associated with | Associated with | ||
---|---|---|---|---|---|---|
Time to Death | Cox regression test | N=1 | shorter survival | N=0 | longer survival | N=1 |
AGE | Spearman correlation test | N=7 | older | N=7 | younger | N=0 |
PRIMARY SITE OF DISEASE | ANOVA test | N=241 | ||||
GENDER | t test | N=1 | male | N=0 | female | N=1 |
DISTANT METASTASIS | ANOVA test | N=248 | ||||
LYMPH NODE METASTASIS | ANOVA test | N=50 | ||||
NEOPLASM DISEASESTAGE | ANOVA test | N=8 |
Time to Death | Duration (Months) | 0.2-357.4 (median=47.5) |
censored | N = 81 | |
death | N = 84 | |
Significant markers | N = 1 | |
associated with shorter survival | 0 | |
associated with longer survival | 1 |
HazardRatio | Wald_P | Q | C_index | |
---|---|---|---|---|
NR4A3 | 0.08 | 1.586e-06 | 0.027 | 0.334 |
AGE | Mean (SD) | 55.92 (16) |
Significant markers | N = 7 | |
pos. correlated | 7 | |
neg. correlated | 0 |
SpearmanCorr | corrP | Q | |
---|---|---|---|
ITGA8 | 0.4068 | 4.881e-08 | 0.000836 |
PTX3 | 0.4035 | 6.408e-08 | 0.0011 |
RSPO4 | 0.3758 | 5.59e-07 | 0.00957 |
SHANK1 | 0.37 | 8.581e-07 | 0.0147 |
TRPV4 | 0.3689 | 9.339e-07 | 0.016 |
CTAGE5 | 0.358 | 2.035e-06 | 0.0348 |
MCHR1 | 0.3539 | 2.707e-06 | 0.0463 |
PRIMARY.SITE.OF.DISEASE | Labels | N |
DISTANT METASTASIS | 25 | |
PRIMARY TUMOR | 1 | |
REGIONAL CUTANEOUS OR SUBCUTANEOUS TISSUE (INCLUDES SATELLITE AND IN-TRANSIT METASTASIS) | 32 | |
REGIONAL LYMPH NODE | 110 | |
Significant markers | N = 241 |
ANOVA_P | Q | |
---|---|---|
DAZAP1 | 1.44e-106 | 2.47e-102 |
TCF3 | 3.169e-51 | 5.43e-47 |
IRAK4 | 8.746e-50 | 1.5e-45 |
PUS7L | 8.746e-50 | 1.5e-45 |
TCF25 | 1.921e-46 | 3.29e-42 |
AMY2B | 5.344e-43 | 9.15e-39 |
NCRNA00175 | 3.823e-42 | 6.55e-38 |
TUBGCP6 | 2.041e-39 | 3.49e-35 |
JPH3 | 1.034e-36 | 1.77e-32 |
ACRV1 | 1.312e-33 | 2.25e-29 |
GENDER | Labels | N |
FEMALE | 65 | |
MALE | 103 | |
Significant markers | N = 1 | |
Higher in MALE | 0 | |
Higher in FEMALE | 1 |
T(pos if higher in 'MALE') | ttestP | Q | AUC | |
---|---|---|---|---|
DDX43 | -4.94 | 1.914e-06 | 0.0328 | 0.7289 |
DISTANT.METASTASIS | Labels | N |
M0 | 145 | |
M1 | 2 | |
M1A | 2 | |
M1B | 2 | |
M1C | 2 | |
Significant markers | N = 248 |
ANOVA_P | Q | |
---|---|---|
SELT | 1.308e-21 | 2.24e-17 |
LMF1 | 4.98e-21 | 8.53e-17 |
FAM186A | 7.522e-21 | 1.29e-16 |
LDHAL6B | 7.709e-21 | 1.32e-16 |
CCNG1 | 1.642e-20 | 2.81e-16 |
RASA2 | 1.03e-19 | 1.76e-15 |
C10ORF88 | 2.823e-19 | 4.83e-15 |
ACSS1 | 5.263e-18 | 9.01e-14 |
MDM1 | 4.519e-17 | 7.74e-13 |
PSMA5 | 1.808e-16 | 3.09e-12 |
LYMPH.NODE.METASTASIS | Labels | N |
N0 | 94 | |
N1 | 2 | |
N1A | 6 | |
N1B | 15 | |
N2 | 1 | |
N2A | 4 | |
N2B | 10 | |
N2C | 5 | |
N3 | 15 | |
NX | 2 | |
Significant markers | N = 50 |
ANOVA_P | Q | |
---|---|---|
NGLY1 | 2.374e-62 | 4.07e-58 |
C6ORF162 | 8.021e-39 | 1.37e-34 |
LIMK2 | 2.75e-36 | 4.71e-32 |
AP2S1 | 2.627e-27 | 4.5e-23 |
C17ORF63 | 1.171e-23 | 2.01e-19 |
NOS1 | 1.906e-22 | 3.26e-18 |
CSRP2BP | 7.661e-19 | 1.31e-14 |
GPR44 | 9.696e-17 | 1.66e-12 |
NHEDC1 | 2.101e-16 | 3.6e-12 |
RRAGA | 1.921e-14 | 3.29e-10 |
NEOPLASM.DISEASESTAGE | Labels | N |
I OR II NOS | 3 | |
STAGE I | 17 | |
STAGE IA | 10 | |
STAGE IB | 14 | |
STAGE II | 19 | |
STAGE IIA | 8 | |
STAGE IIB | 10 | |
STAGE IIC | 8 | |
STAGE III | 8 | |
STAGE IIIA | 5 | |
STAGE IIIB | 17 | |
STAGE IIIC | 22 | |
STAGE IV | 6 | |
Significant markers | N = 8 |
-
Expresson data file = SKCM-All_Metastatic.meth.for_correlation.filtered_data.txt
-
Clinical data file = SKCM-All_Metastatic.clin.merged.picked.txt
-
Number of patients = 168
-
Number of genes = 17129
-
Number of clinical features = 7
For survival clinical features, Wald's test in univariate Cox regression analysis with proportional hazards model (Andersen and Gill 1982) was used to estimate the P values using the 'coxph' function in R. Kaplan-Meier survival curves were plot using the four quartile subgroups of patients based on expression levels
For continuous numerical clinical features, Spearman's rank correlation coefficients (Spearman 1904) and two-tailed P values were estimated using 'cor.test' function in R
For multi-class clinical features (ordinal or nominal), one-way analysis of variance (Howell 2002) was applied to compare the log2-expression levels between different clinical classes using 'anova' function in R
For two-class clinical features, two-tailed Student's t test with unequal variance (Lehmann and Romano 2005) was applied to compare the log2-expression levels between the two clinical classes using 't.test' function in R
For multiple hypothesis correction, Q value is the False Discovery Rate (FDR) analogue of the P value (Benjamini and Hochberg 1995), defined as the minimum FDR at which the test may be called significant. We used the 'Benjamini and Hochberg' method of 'p.adjust' function in R to convert P values into Q values.
This is an experimental feature. The full results of the analysis summarized in this report can be downloaded from the TCGA Data Coordination Center.